Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Brain region specific actions of regulator of G protein signaling 4 oppose morphine reward and dependence but promote analgesia.

Han MH, Renthal W, Ring RH, Rahman Z, Psifogeorgou K, Howland D, Birnbaum S, Young K, Neve R, Nestler EJ, Zachariou V.

Biol Psychiatry. 2010 Apr 15;67(8):761-9. doi: 10.1016/j.biopsych.2009.08.041.

2.

Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine.

Gaspari S, Papachatzaki MM, Koo JW, Carr FB, Tsimpanouli ME, Stergiou E, Bagot RC, Ferguson D, Mouzon E, Chakravarty S, Deisseroth K, Lobo MK, Zachariou V.

Neuropsychopharmacology. 2014 Jul;39(8):1968-77. doi: 10.1038/npp.2014.45.

3.

A unique role of RGS9-2 in the striatum as a positive or negative regulator of opiate analgesia.

Psifogeorgou K, Terzi D, Papachatzaki MM, Varidaki A, Ferguson D, Gold SJ, Zachariou V.

J Neurosci. 2011 Apr 13;31(15):5617-24. doi: 10.1523/JNEUROSCI.4146-10.2011. Erratum in: J Neurosci. 2011 May 18;31(20):7578. Psigfogeorgou, Kassi [corrected to Psifogeorgou, Kassi].

4.

Regulator of G protein signaling 4 [corrected] is a crucial modulator of antidepressant drug action in depression and neuropathic pain models.

Stratinaki M, Varidaki A, Mitsi V, Ghose S, Magida J, Dias C, Russo SJ, Vialou V, Caldarone BJ, Tamminga CA, Nestler EJ, Zachariou V.

Proc Natl Acad Sci U S A. 2013 May 14;110(20):8254-9. doi: 10.1073/pnas.1214696110. Erratum in: Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11660.

5.

Splicing factor transformer-2β (Tra2β) regulates the expression of regulator of G protein signaling 4 (RGS4) gene and is induced by morphine.

Li SJ, Li Y, Cui SC, Qi Y, Zhao JJ, Liu XY, Xu P, Chen XH.

PLoS One. 2013 Aug 19;8(8):e72220. doi: 10.1371/journal.pone.0072220.

6.

RGSZ1 and GAIP regulate mu- but not delta-opioid receptors in mouse CNS: role in tachyphylaxis and acute tolerance.

Garzón J, Rodríguez-Muñoz M, López-Fando A, García-España A, Sánchez-Blázquez P.

Neuropsychopharmacology. 2004 Jun;29(6):1091-104.

7.

Intrathecal RGS4 inhibitor, CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test.

Yoon SY, Woo J, Park JO, Choi EJ, Shin HS, Roh DH, Kim KS.

Anesth Analg. 2015 Mar;120(3):671-7. doi: 10.1213/ANE.0000000000000607.

PMID:
25695583
8.

Essential role for RGS9 in opiate action.

Zachariou V, Georgescu D, Sanchez N, Rahman Z, DiLeone R, Berton O, Neve RL, Sim-Selley LJ, Selley DE, Gold SJ, Nestler EJ.

Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13656-61.

9.

The RGSZ2 protein exists in a complex with mu-opioid receptors and regulates the desensitizing capacity of Gz proteins.

Garzón J, Rodríguez-Muñoz M, López-Fando A, Sánchez-Blázquez P.

Neuropsychopharmacology. 2005 Sep;30(9):1632-48.

10.

Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5.

Glück L, Loktev A, Moulédous L, Mollereau C, Law PY, Schulz S.

Biol Psychiatry. 2014 Nov 15;76(10):767-74. doi: 10.1016/j.biopsych.2014.01.021.

11.

R7BP modulates opiate analgesia and tolerance but not withdrawal.

Terzi D, Cao Y, Agrimaki I, Martemyanov KA, Zachariou V.

Neuropsychopharmacology. 2012 Mar;37(4):1005-12. doi: 10.1038/npp.2011.284.

12.

Galanin protects against behavioral and neurochemical correlates of opiate reward.

Hawes JJ, Brunzell DH, Narasimhaiah R, Langel U, Wynick D, Picciotto MR.

Neuropsychopharmacology. 2008 Jul;33(8):1864-73.

13.

Regulation of RGS proteins by chronic morphine in rat locus coeruleus.

Gold SJ, Han MH, Herman AE, Ni YG, Pudiak CM, Aghajanian GK, Liu RJ, Potts BW, Mumby SM, Nestler EJ.

Eur J Neurosci. 2003 Mar;17(5):971-80.

PMID:
12653973
14.

RGS9 proteins facilitate acute tolerance to mu-opioid effects.

Garzón J, Rodríguez-Díaz M, López-Fando A, Sánchez-Blázquez P.

Eur J Neurosci. 2001 Feb;13(4):801-11.

PMID:
11207815
15.

Differential control of opioid antinociception to thermal stimuli in a knock-in mouse expressing regulator of G-protein signaling-insensitive Gαo protein.

Lamberts JT, Smith CE, Li MH, Ingram SL, Neubig RR, Traynor JR.

J Neurosci. 2013 Mar 6;33(10):4369-77. doi: 10.1523/JNEUROSCI.5470-12.2013.

16.

RGS9-2 is a negative modulator of mu-opioid receptor function.

Psifogeorgou K, Papakosta P, Russo SJ, Neve RL, Kardassis D, Gold SJ, Zachariou V.

J Neurochem. 2007 Oct;103(2):617-25.

17.

Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve.

Sora I, Elmer G, Funada M, Pieper J, Li XF, Hall FS, Uhl GR.

Neuropsychopharmacology. 2001 Jul;25(1):41-54.

18.

A role of RGS proteins in drug addiction.

Hooks SB, Martemyanov K, Zachariou V.

Biochem Pharmacol. 2008 Jan 1;75(1):76-84. Review.

PMID:
17880927
19.

Morphine alters the selective association between mu-opioid receptors and specific RGS proteins in mouse periaqueductal gray matter.

Garzón J, Rodríguez-Muñoz M, Sánchez-Blázquez P.

Neuropharmacology. 2005 May;48(6):853-68.

PMID:
15829256
20.
Items per page

Supplemental Content

Support Center